
David Pass | AltrixBio - Gut-Targeted Oral Therapy for Diabetes and Obesity
In this episode of Executive Insights for Life Sciences Innovators, Don Alexander speaks with David Pass, CEO and President of AltrixBio. David discusses AltrixBio’s work to advance AJN003, a once-daily, oral, gut-target








